

## Special Issue

# Selected Papers from International Vaccines Congress 2020

### Message from the Guest Editor

International [Vaccines Congress 2020](#) which will be held on 29–31 October, 2020 in Orlando, USA serves as a podium for the interaction between experts in the area of Vaccines around the globe and aims in sharing some unique research with the researchers, industry representatives working in this exciting area. It is expected to bring together both eminent scientists in advanced stages of their career and young researchers from many related disciplines. [IVC 2020](#) expects many new ideas to emerge at the interfaces between disciplines aiming to solve the most important problems relating to the health and wellbeing of the humanity.

[Vaccines 2020 conferences](#) with its strong emphasis on innovative approaches, it offers a chance for scientists and physicians working in different areas of Vaccines development to learn novel ideas that could benefit them advance their own research and forge new professional relationships and collaborations. More information about the conference can be found at <https://www.vaccinescongress.com/>

---

### Guest Editor

Dr. Giuseppe Bardi

Nanobiointeractions & Nanodiagnostics, Istituto Italiano di Tecnologia,  
Via Morego 30, 16163 Genova, Italy

---

### Deadline for manuscript submissions

closed (30 November 2020)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/36931](https://mdpi.com/si/36931)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).